Summit Therapeutics (SMMT) EBIT (2017 - 2024)
Summit Therapeutics' (SMMT) quarterly EBIT came in at -$65.6 million in Q4 2024, down 81.2% YoY from -$349.1 million in Q1 2024, and down 12.4% on a QoQ basis from -$58.4 million in Q3 2024.
Summit Therapeutics (SMMT) EBIT (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of EBIT data on file, last reported at -$65.6 million in Q4 2024.
- Quarterly EBIT fell 81.2% year-over-year to -$65.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$226.0 million (up 62.93% YoY) and the FY2024 annual result came in at -$226.0 million, up 62.93% from the prior year.
- EBIT retreated to -$65.6 million in Q4 2024, from -$58.4 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$11.6 million in Q4 2020 to a low of -$537.2 million in Q1 2023.
- A 5-year average of -$52.9 million and a median of -$20.6 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2023 — EBIT slumped 2324.2% — and 2024, when it jumped 92.11%.
- Tracing SMMT's EBIT over 5 years: stood at -$11.6 million in 2020, then plunged by 125.4% to -$26.0 million in 2021, then advanced by 22.07% to -$20.3 million in 2022, then plunged by 78.38% to -$36.2 million in 2023, then tumbled by 81.2% to -$65.6 million in 2024.
- The last three EBIT figures came in at -$65.6 million (Q4 2024), -$58.4 million (Q3 2024), and -$59.6 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.61 Mn |
| Sep 30, 2024 | -58.38 Mn |
| Jun 30, 2024 | -59.62 Mn |
| Mar 31, 2024 | -42.39 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -537.15 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -26.05 Mn |
| Sep 30, 2021 | -19.49 Mn |
| Jun 30, 2021 | -23.73 Mn |
| Mar 31, 2021 | -16.92 Mn |
| Dec 31, 2020 | -11.56 Mn |
| Sep 30, 2020 | -16.94 Mn |
| Jun 30, 2020 | -15.36 Mn |
| Mar 31, 2020 | -20.77 Mn |